Option chain shows key data for Esports Entertainment's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Esports Entertainment.

Esports Entertainment (OTC:GMBLP) Stock, Option Chain

Esports Entertainment Group Inc is a full-service esports and online betting company. It focuses on three verticals: Games, iGaming, and Technology. EEG Games provides a wide array of services and infrastructure for businesses to engage esports and gaming communities around the world including Esports Gaming League (EGL), which hosts a community of gamers on its proprietary tournament platform EGL.tv. EEG iGaming includes a number of award-winning brands covering traditional online sports book wagering needs as well as a multinational casino operator.

ESPORTS ENTMNT GRP PFD by Esports Entertainment Group, Inc.

Esports Entertainment Group Inc

Analysts' ratings for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00, and a low estimate of $105.00. A 8.65% drop is evident in the current average compared to the previous average price target of $159.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1734958894_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Novo Nordisk. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$156.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Novo Nordisk. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Novo Nordisk compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Novo Nordisk's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NVO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Novo Nordisk analyst ratings.</a>
<h2>Get to Know Novo Nordisk Better</h2>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Novo Nordisk: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Novo Nordisk displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 21.42%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Novo Nordisk's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.28% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Novo Nordisk's ROE excels beyond industry benchmarks, reaching 23.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Novo Nordisk's ROA stands out, surpassing industry averages. With an impressive ROA of 7.12%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Novo Nordisk Stock

News

INVZ

Innoviz Secures $80M Multi-Year NRE Payment Plan With Key Customers; Expects $40M In 2025 And Additional Revenue From Ongoing LiDAR Sales And New Programs

In the latest quarter, 4 analysts provided ratings for Encore Capital Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECPG#NASDAQ">ECPG</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Encore Capital Gr, presenting an average target of $62.25, a high estimate of $66.00, and a low estimate of $58.00. This current average has increased by 6.87% from the previous average price target of $58.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1734958871_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Encore Capital Gr by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Encore Capital Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Encore Capital Gr compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Encore Capital Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Encore Capital Gr's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ECPG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Encore Capital Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Encore Capital Gr: A Closer Look</h2>
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchase portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumer repay their obligations and work toward financial recovery. Encore has only a reportable segment being portfolio purchasing and recovery.
<h3>Financial Milestones: Encore Capital Gr's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Encore Capital Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.56% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Encore Capital Gr's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 8.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Encore Capital Gr's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.01%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Encore Capital Gr's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.62%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 3.39, Encore Capital Gr faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ECPG

Analyst Expectations For Encore Capital Gr's Future

In the last three months, 4 analysts have published ratings on PotlatchDeltic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for PotlatchDeltic, presenting an average target of $47.75, a high estimate of $51.00, and a low estimate of $45.00. This current average has increased by 0.17% from the previous average price target of $47.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1734958857_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of PotlatchDeltic by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buck Horne</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Ketan Mamtora</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Matthew McKellar</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PotlatchDeltic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of PotlatchDeltic compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of PotlatchDeltic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of PotlatchDeltic's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PCH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PotlatchDeltic analyst ratings.</a>
<h2>All You Need to Know About PotlatchDeltic</h2>
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.
<h3>Unraveling the Financial Story of PotlatchDeltic</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining PotlatchDeltic's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -3.91% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: PotlatchDeltic's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.3%, the company may face hurdles in effective cost management.
Return on Equity (ROE): PotlatchDeltic's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.16%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): PotlatchDeltic's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.1%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: PotlatchDeltic's debt-to-equity ratio is below the industry average. With a ratio of 0.5, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For PotlatchDeltic's Future

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on CEVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CEVA, revealing an average target of $34.5, a high estimate of $40.00, and a low estimate of $28.00. Witnessing a positive shift, the current average has risen by 23.21% from the previous average price target of $28.00.
<img src="https://www.benzinga.com/files/images/story/2024/1734958831_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive CEVA is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gus Richard</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Suji Desilva</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CEVA. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CEVA compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CEVA's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of CEVA's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CEVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CEVA analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind CEVA</h2>
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.
<h3>CEVA: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: CEVA displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 13.02%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: CEVA's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.82%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CEVA's ROE excels beyond industry benchmarks, reaching -0.5%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): CEVA's ROA excels beyond industry benchmarks, reaching -0.43%. This signifies efficient management of assets and strong financial health.
Debt Management: CEVA's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CEVA

Deep Dive Into CEVA Stock: Analyst Perspectives (4 Ratings)

Cigna's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) short percent of float has fallen 10.85% since its last report. The company recently reported that it has 3.19 million shares sold short, which is 1.15% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cigna Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734958826_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cigna has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cigna's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cigna's peer group average for short interest as a percentage of float is 8.21%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Cigna's Recent Short Interest

Discover Financial Restates Diluted EPS For Quarter Ended Sept 30, 2024 To $3.32

Casella Waste Sys's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWST#NYSE">CWST</a>) short percent of float has risen 7.5% since its last report. The company recently reported that it has 2.13 million shares sold short, which is 3.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Casella Waste Sys Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734958821_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Casella Waste Sys has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Casella Waste Sys's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Casella Waste Sys's peer group average for short interest as a percentage of float is 3.18%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CWST

How Is The Market Feeling About Casella Waste Sys?

Blackstone's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) short percent of float has fallen 3.0% since its last report. The company recently reported that it has 16.43 million shares sold short, which is 2.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Blackstone Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734958815_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Blackstone has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Blackstone's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Blackstone's peer group average for short interest as a percentage of float is 3.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Blackstone's Recent Short Interest

BMO Capital analyst Jeffrey Silber maintains FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) with a Market Perform and lowers the price target from $521 to $518.

Price Target

BMO Capital Maintains Market Perform on FactSet Research Systems, Lowers Price Target to $518

BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) with a Outperform and lowers the price target from $156 to $105.

BMO Capital Maintains Outperform on Novo Nordisk, Lowers Price Target to $105

AILEW

Trading Halt: Halted at 7:56:15 a.m. ET - Trading Halt: Halt News Pending

AILE

Citigroup analyst William Katz maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Buy and raises the price target from $1150 to $1200.

Citigroup Maintains Buy on BlackRock, Raises Price Target to $1200

BTIG analyst Thomas Catherwood downgrades Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Buy to Neutral.

Downgrades

IIPR

BTIG Downgrades Innovative Ind Props to Neutral

Northland Capital Markets analyst Mike Grondahl maintains Encore Capital Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECPG#NASDAQ">ECPG</a>) with a Outperform and raises the price target from $58 to $66.

Northland Capital Markets Maintains Outperform on Encore Capital Gr, Raises Price Target to $66

Northland Capital Markets analyst Gus Richard maintains CEVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>) with a Outperform and raises the price target from $31 to $35.

Northland Capital Markets Maintains Outperform on CEVA, Raises Price Target to $35

At the beginning of 2024, Benzinga noted <a target="_blank" href="https://www.benzinga.com/markets/commodities/24/01/36452207/4-mining-stocks-to-watch-in-2024-aura-oceanagold-alphamin-b2gold" rel="noreferrer noopener">four mining stocks</a> to follow while evaluating tailwinds like green tech demand and persistent inflation. Although gold, as a benchmark, has had one of the best years on record, outperforming even the surging equities market, miners delivered mixed results.
<h3 class="wp-block-heading">Aura Minerals</h3>
Aura Minerals (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ORAAF#OTCQX">ORAAF</a>) is a gold and copper miner focused on Central and South America, with primary operations in Brazil, Mexico, and Honduras. During 2024, the company made notable asset acquisitions, obtaining rights to explore Pé Quente and Pezão projects to boost its reserves. The company also acquired Bluestone Resources, a junior miner with a promising high-grade gold deposit in Guatemala.
The company recently reported its second-best quarter by adjusted EBITDA and decreased all-in-sustained costs to $1,292/ounce. The stock was a strong performer, rising 85% year-to-date.
<h3 class="wp-block-heading">OceanaGold</h3>
OceanaGold (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OCANF#OTC">OCANF</a>) is a mid-tier gold and copper producer with production in New Zealand, the Philippines, and the United States. It originally started as Macraes Mining Company, named after the foundation asset in New Zealand, which produced over 5 million ounces of gold since 1990. During 2024, the company focused on advancing the Didipio gold and copper project in the Philippines and providing initial mineral reserves for the proposed Wharekirauponga gold mine in New Zealand of 1.2 million ounces, with a projected IRR of 24% at a gold price of $2,400 per ounce.
Per the latest earnings, the company increased quarterly production from all sites, achieving a net profit of $61 million and boosting cash reserves. Since the beginning of the year, the stock rose 60.4%.
<h3 class="wp-block-heading">Alphamin Resources</h3>
Alphamin Resources (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AFMJF#OTC">AFMJF</a>) is a miner focused on producing tin, a critical mineral used for metal coating and the production of superconducting magnets. The company's principal project is the Bisie mine, the world's highest-grade tin mine.
In 2024, Alphamin achieved record quarterly tin production, in excess of 4,000 tons, staying on track to its production target of 20,000 tons annually. For the next growth step, the firm plans to connect its mining sites to have one producing unit feeding two processing facilities. Management estimates they could scale up output to 25,000 tons. The last drill campaign added 175,000 tons of reserves. Alphamin's stock returned 21.1% year-to-date.
<h3 class="wp-block-heading">B2Gold</h3>
B2Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTG#AMEX">BTG</a>) is a mid-tier mining company operating mines in emerging markets and exploration activities in more stable jurisdictions like Canada and Finland. The company's principal asset is the Fekola mine in Mali, with an annual production exceeding 500,000 ounces. Its other operating assets include Masabe in the Philippines and Otjikoto in Namibia.B2Gold had a volatile year, as <a target="_blank" href="https://www.benzinga.com/news/guidance/24/12/42516175/barrick-warns-about-destabilization-in-mali-could-halt-one-of-its-largest-mines" rel="noreferrer noopener">escalating instability in Mali</a> resulted in the off-site deaths of multiple employees and an increasingly complex situation with the ruling military junta. Furthermore, the higher-than-anticipated capital costs for a project in northern Canada have weighed on financials. Owing to these setbacks, B2Gold has lost 14.4% year-to-date.
As of December 20, VanEck Junior Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDXJ#NYSE">GDXJ</a>) returned 16.67% year-to-date.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42628973/billionaire-investor-bullish-on-gold-miners-including-this-penny-stock" target="_blank" rel="noreferrer noopener">Billionaire John Paulson Bullish On Gold Miners, Including This Penny Stock</a></li>
</ul>
Image via Shutterstock

Commodities

AFMJF

GDXJ

OCANF

ORAAF

Reviewing Benzinga's Mining Watchlist For 2024

COSCIENS Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCI#NASDAQ">CSCI</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CSCI#TSX">CSCI</a>) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today provided a corporate update and reiterated its pipeline prioritization.
"Over the course of the last several months following the merger, we have taken strategic and deliberate steps to evaluate and prioritize our combined pipeline of products and programs. Through this effort, we have thoroughly evaluated the potential of our assets and prioritized the areas that we believe are high-value opportunities, and we plan to move forward focusing our resources on advancing a pipeline of natural-based products leveraging our core technologies. We believe that this focus, spanning cosmeceuticals, nutraceuticals and pharmaceuticals, positions us with near and long-term life science growth drivers and the potential to become a global leader in natural-based products for health and wellness," stated <a href="https://www.globenewswire.com/Tracker?data=XGEB5e3QJGs0rAZIEn9x3enzUNiQFyPKt0kKPnr1xjTKfNlMsAdacP2YgVUlHhRD5gSQwGVhUPozg71YRlEgMHW38CEK1DDrHxEAYh0ecfkZ-ZDfyBuCxSyjQEpSMY-zoQ4WmYnYksKrGXJWHDk_2w==">Gilles Gagnon, M.Sc., MBA, President and CEO</a> of COSCIENS. "In addition, we have continued to make progress driving revenues and growing our active ingredients base business. We are looking to kick off 2025 with a clear line of sight towards execution of our business plan and believe we are well-positioned for a transformational year."
Development Projects Update
Pharmaceuticals:
<ul>
<li>Avenanthramides Tablets (Avs) in Development as an Anti-Inflammatory: The Phase 1-2a clinical trial being conducted at the Montreal Heart Institute has fully completed the Phase 1 part of the study with 72 subjects tested. No significant side effects have been observed from ascending doses ranging from 30 mg to 960 mg. The Company expects the Phase 2a efficacy study will be initiated in Q1 2025, with expected completion in Q3 2025. &nbsp;</li>
</ul>
Cosmeceuticals:
<ul>
<li>Enriched Oat Flour with High Concentration of Avenanthramides: We have successfully produced and sold small batches for inclusion in cream formulations. &nbsp;</li>
<li>JuventeDC Product Line: New website, <a href="https://juventedc.com/en">juventedc.com</a>, was launched on December 19, 2024. &nbsp;</li>
</ul>
Nutraceuticals:
<ul>
<li>Yeast Beta Glucan (YBG) Powder - Immune Booster: Our YBG product has been successfully manufactured as part of our PGX scale up project in Edmonton, Alberta. Our YBG product is being finalized in capsule form with the goal to commercialize it as an immune booster in Q2 2025. &nbsp;</li>
<li>Oat Beta Glucan (OBG) Chewable Bar – Cholesterol Reduction: We have successfully developed a unique, standardized formulation for a healthy confection which includes a high concentration of OBG with daily dosage according to approved claims in 10 developed countries. The substantive claims include reduction of LDL cholesterol, supporting cardiovascular health reduction of Type 2 diabetes risks, source of fiber for the maintenance of general good health and support of a healthy digestive system. COSCIENS' team anticipates the official commercial launch of its chewable bar OBG natural health product in Q1 2025, marking an important chapter in the Company's journey toward promoting wellness while expanding its business model. &nbsp;</li>
</ul>
Macimorelin:
<ul>
<li>On August 27, 2024, the Company announced that the Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency ("CGHD") had failed to meet its primary endpoints according to the definitions in the study protocol. Based on the results of the study, we are prioritizing our pipeline moving forward and repositioning the Company as a pure play Life Science's business offering natural-based products. Therefore, while maintaining the current commercial indication for the use of macimorelin for the diagnosis of Adult Growth Hormone Deficiency ("AGHD"), the Company has decided to not make any future investments in macimorelin for the diagnosis of CGHD. Consequently, in order to further ensure the streamlining of operations and reduce costs, the roles of some additional members of management have been terminated, including Dr. Nicola Ammer, Chief Medical Officer, which will be ending on March 31, 2025. &nbsp;</li>
</ul>

CSCI

TSX:CSCI

COSCIENS Biopharma Shifts Focus to Natural-Based Products for Health & Wellness

Barclays analyst David Strauss maintains Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) with a Overweight and lowers the price target from $104 to $95.

Comments

Esports Entertainment

Esports Entertainment (GMBLP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga